Among them, the adenosine A2A receptor (A2A-R) has drawn attention as a potential therapeutic drug target in HD because it is highly prevalent in the striatum where mutant huntingtin (Htt) causes selective neural cell loss and atrophy. This evidence concerns the gene ADORA2A and Huntington disease.